Our lead pipeline candidate, etripamil, is a proprietary chemical entity that was conceived, discovered, and optimized by Milestone.

Milestone is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug, etripamil, for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT). Milestone has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Etripamil is not currently approved for the treatment of PSVT, AFib with RVR, or for any other indication anywhere in the world.